Completed PHASE2 INTERVENTIONAL 2-arm NCT03700580

Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer (P1G10)

Application of a Double Blind Clinical Trial Protocol for Evaluation of Healing Action of P1G10, From V Cundinamarcensis to Chronic Neuropathic Wounds in Diabetic Foot Ulcers.

Sponsor: Carlos E Salas

Conditions Diabetic Foot Foot Ulcer Neuropathy, Diabetic

Interventions Hydrogel treatment P1G10

Updated 4 times since 2018 Last updated: Oct 8, 2018 Started: Aug 15, 2012 Primary completion: Oct 14, 2016 Completion: Oct 15, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03700580, this PHASE2 trial focuses on Diabetic Foot and Foot Ulcer and remains completed. Sponsored by Carlos E Salas, it has been updated 4 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Carlos E Salas

Data source: Federal University of Minas Gerais

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Belo Horizonte, Brazil